Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers
On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading…
On Wednesday, Moderna (MRNA) experienced an unprecedented surge in its stock price, skyrocketing by a record-breaking 101%. This remarkable gain marked the largest intraday increase ever recorded for the biotech company. The driving force behind this meteoric rise was Moderna's announcement that a personalized cancer vaccine, in collaboration with Merck & Co.'s Keytruda, had led to a significant reduction in melanoma recurrence during a large-scale, late-stage trial.
Furthermore, the study met a crucial secondary objective by demonstrating the vaccine's potential to prevent tumors from metastasizing to other parts of the body.
Meanwhile, Estee Lauder (EL) also saw its shares rally following the beauty company's announcement that its adjusted earnings per share and sales metrics exceeded consensus expectations for the fourth quarter. The midpoint of the company's fiscal 2027 organic sales and adjusted EPS guidance ranges were found to be higher than those projected by analysts.
In contrast to these positive developments, La-Z-Boy (LZB) faced a significant downturn in its stock price at the opening bell. The furniture manufacturer's forecast for Q2 sales fell short of the average analyst estimate, leading to a sharp decline in its share price.
Written by urgent.news from Bloomberg's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
